New blood: Terumo BCT CEO set to shape future of blood, cell technologies

KUALA LUMPUR, April 2 (Bernama) -- New Terumo BCT president and chief executive officer, Antoinette Gawin has expanded the company beyond its heritage in working with blood centres and hospitals to serve rapidly growing areas of healthcare.

She focuses on the company’s potential to treat disease and play a greater role in cell therapy and regenerative medicine, to serve more patients as Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas.

“Our innovations automate complex processes, help researchers and clinicians unlock the healing potential of an individual’s genetic material. We must diversify our portfolio to fund continued innovation in this cost-conscious healthcare environment and remain relevant to our customers,” said Gawin.

Strategies include embedding products in the cell therapy manufacturing process, increasing the awareness of therapeutic apheresis as a treatment to address autoimmune diseases and building infrastructure in growth geographies, among others.

Gawin, who succeeds David Perez, will oversee the company with nearly US$1 billion (US$1 = RM4.08) in revenue and 7,000 associates supporting customers in 130 countries.

She joined Terumo BCT in 2016 as executive vice-president (global commercial), bringing nearly 30 years’ experience directing diverse global teams and transformational change across Baxter and GE.

Terumo BCT is a biomedical company and global leader in blood component, therapeutic apheresis and cell therapy technologies. For more information, contact https://www.terumobct.com.

-- BERNAMA